Search - tctmd.com

Displaying 321 - 340 of 831

Sort: Relevancy | Date

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) from: EXCEL and NOBLE

Presenter: Yves R. Louvard, John D. Puskas, Davide Capodanno

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Presenter: Philip M. Urban, Stephen G. Worthley, Bonnie H. Weiner

November 01, 2016

Presentation TCT 2016

Radiation Exposure and Protection

Presenter: Charles E. Chambers, Stephen Balter

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Dmitriy N. Feldman, Emmanouil S. Brilakis

November 01, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Presenter: Philip M. Urban, Stephen G. Worthley, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

Complications Related to Contrast and Commonly Used Medications

Presenter: Giora Weisz, Payam Dehghani

November 01, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

2016 CTO Revascularization Update

Presenter: Sripal Bangalore, George D. Dangas, Khaldoon Alaswad

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

2016 STEMI PCI Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2016

2016 DAPT Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla

November 01, 2016

Advertisement

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Highlights (and my Interpretations) from: EXCEL and NOBLE

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Radiation Exposure and Protection

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

FDA Perspectives on Short DAPT IDE Trials

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Complications Related to Contrast and Commonly Used Medications

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

2016 CTO Revascularization Update

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

2016 STEMI PCI Update: Evidence and Guidelines

2016 DAPT Update: Evidence and Guidelines

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content